Table 4.
Baseline characteristics of the patients included in the study.
| Variables | Groups | Total | p | ||
|---|---|---|---|---|---|
| G1 | G2 | G3 | |||
| Median Age (IQR) | 74 (67.5–78.5) | 60.5 (52.25–71.75) | 72 (61.5–81) | 71.5 (60.75–78.25) | 0.136 * |
| Gender | |||||
| Female | 8 | 8 | 10 | 26 | 0.13 |
| 61.50% | 100.00% | 76.90% | 76.50% | ||
| Male | 5 | 0 | 3 | 8 | |
| 38.50% | 0.00% | 23.10% | 23.50% | ||
| Neoplastic diseases | 10 | 7 | 11 | 28 | 0.796 |
| 76.90% | 87.50% | 84.60% | 82.40% | ||
| Osteoporosis | 3 | 1 | 2 | 6 | 0.796 |
| 23.10% | 12.50% | 15.40% | 17.60% | ||
| Antiresorptive and/or antiangiogenic medications | |||||
| Bisphosphonate | 7 | 3 | 8 | 18 | 0.53 |
| 53.80% | 37.50% | 61.50% | 52.90% | ||
| both | 2 | 3 | 1 | 6 | |
| 15.40% | 37.50% | 7.70% | 17.60% | ||
| Denosumab | 4 | 2 | 4 | 10 | |
| 30.80% | 25.00% | 30.80% | 29.40% | ||
| Median MRONJ-related drugs therapy duration (months—IQR) | 30 (16.5–60) | 30.5 (24–55.5) | 24 (22.5–40.5) | 29.5 (22.75–48) | 0.599 * |
| Corticosteroids | 4 | 0 | 7 | 11 | 0.037 |
| 30.80% | 0.00% | 53.80% | 32.40% | ||
| Chemotherapy | 10 | 7 | 11 | 28 | 0.796 |
| 76.90% | 87.50% | 84.60% | 82.40% | ||
| Diabetes | 1 | 1 | 2 | 4 | 0.829 |
| 7.70% | 12.50% | 15.40% | 11,80% | ||
| Smoking habit | 6 | 0 | 1 | 7 | 0.014 |
| 46.20% | 0.00% | 7.70% | 20.60% | ||
| MRONJ Stage | |||||
| 1 | 3 | 2 | 6 | 11 | 0.399 |
| 23.10% | 25.00% | 46.20% | 32.40% | ||
| 2 | 10 | 6 | 7 | 23 | |
| 76.90% | 75.00% | 53.80% | 67.60% | ||
| MRONJ localization | |||||
| mandible | 9 | 4 | 6 | 19 | 0.461 |
| 69.20% | 50.00% | 46.20% | 55.90% | ||
| maxilla | 4 | 4 | 7 | 15 | |
| 30,80% | 50.00% | 53.80% | 44.10% | ||
| Total | 13 | 8 | 13 | 34 | |
| 100.00% | 100.00% | 100.00% | 100.00% | ||
IQR: interquartile range; * Kruskal–Wallis test.